G+FLAS Life Sciences

By way of example, we are developing biosimilars (biobetters) using our non-GMO method of plant genome editing technology. We developed a glycoengineered humanized plant in which glycosylation-related genes were selectively removed from the plants using the CRISPR-PLUS ™ technology. Then, based on this transgenic plant, we are developing immunotherapeutic anticancer biobetter drugs such as Trastuzumab. G+FLAS Life Sciences, Inc. was selected as a TIPS company by the Ministry of SMEs and Startups (MSS) of South Korea government in 2016 and secured 4.2 billion KRW ($3.7 million USD) Series A funds from domestic institutional investors such as KDB Bank in 2017. In the first half of 2018, we successfully secured Series B funding. Soon, another successful Series C funding securement was accomplished in the following year. With these funds, we will accelerate many promising projects such as CRISPR-based immunotherapeutic anticancer drug development, global open innovation, application for clinical trials of plant-based biobetters (IND), and pilot research and production facilities at the Osong Hi-Tech Composite Medical Complex in Chungbuk. G+FLAS Life Sciences, Inc. is well position and will strive to do our best to research and develop biopharmaceuticals using nature-friendly plants to treat all kinds of human diseases. We greatly appreciate your supports and participation in the global new drug development challenge for saving people's lives around the world. Suite 1F, 38 Nakseongdae-ro, Gwanak-Gu, Seoul 08790, Korea